glp-1 obesity drug news october 2025 Eli Lilly set to leapfrog Novo Nordisk in weight-loss race Alarming rise in weight loss

Authors: Karen G Farrar University of Southern California , Los Angeles, CA, Duy Do Truveta, Inc , Bellevue, WA, Nina B Masters Truveta, Inc , Bellevue, WA, Brianna M Cartwright Truveta, Inc , Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred formulary option in July 2025, switching from anti-obesity tirzepatide surged from 0.6% to 9.7%, representing more than a 16-fold rise

GLP-1 agonist liraglutide prevents MK-801-induced schizophrenia-like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice

doi:10.1016/j.addr.2018.07.009 6

Why Muscle Support Matters for Metabolism This is the part many people overlook when they start to take a GLP-1 injectable

For women with obesity, it is uncertain how much weight loss may be required to improve pregnancy outcomes, and it is uncertain how best to achieve this weight loss while maintaining maternal nutrition

More importantly, the better management of GI AEs could potentially have a positive impact on the adherence/persistence, effectiveness of treatment and quality of life (QoL) among GLP-1 RA-treated patients